

1 **Three-dimensional spatial transcriptomics uncovers cell type dynamics in the**  
2 **rheumatoid arthritis synovium**

3 Sanja Vickovic<sup>1,\*</sup>, Denis Schapiro<sup>1,2†</sup>, Konstantin Carlberg<sup>3,†</sup>, Britta Lötstedt<sup>1,3†</sup>, Ludvig  
4 Larsson<sup>3,†</sup>, Marina Korotkova<sup>4,5</sup>, Aase H Henvold<sup>4,5</sup>, Anca I Catrina<sup>4,5</sup>, Peter K Sorger<sup>2</sup>,  
5 Vivianne Malmström<sup>4,5</sup>, Aviv Regev<sup>1,6,7</sup>, Patrik L Ståhl<sup>3</sup>

6 <sup>†</sup>These authors contributed equally to this work

7 \*To whom correspondence should be addressed: [vickovic@broadinstitute.org](mailto:vickovic@broadinstitute.org) (S.V)

8

9 <sup>1</sup>Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.

10 <sup>2</sup>Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA

11 <sup>3</sup>Science for Life Laboratory, Department of Gene Technology, KTH Royal Institute of  
12 Technology, Stockholm, Sweden

13 <sup>4</sup>Karolinska Institutet, Division of Rheumatology, Department of Medicine, Center for Molecular  
14 Medicine, Stockholm, Sweden

15 <sup>5</sup>Karolinska University Hospital, Unit of Rheumatology, Stockholm, Sweden

16 <sup>6</sup>Howard Hughes Medical Institute and Koch Institute for Integrative Cancer Research,  
17 Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA

18 <sup>7</sup>Current address: Genentech, 1 DNA Way, South San Francisco, CA, USA

19 **Abstract**

20 **The inflamed rheumatic joint is a highly heterogeneous and complex tissue with dynamic**  
21 **recruitment and expansion of multiple cell types that interact in multifaceted ways within a**  
22 **localized area. Rheumatoid arthritis synovium has primarily been studied either by**  
23 **immunostaining or by molecular profiling after tissue homogenization. Here, we use**  
24 **Spatial Transcriptomics to study local cellular interactions at the site of chronic synovial**  
25 **inflammation. We report comprehensive spatial RNA-seq data coupled to quantitative and**  
26 **cell type-specific chemokine-driven dynamics at and around organized structures of**  
27 **infiltrating leukocyte cells in the synovium.**

28 Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the joints. It  
29 consists of two broad subsets, seropositive and seronegative. Seropositive RA, comprises two  
30 thirds of patients, who often exhibit more severe symptoms, is a classical autoimmune disease  
31 defined by the presence of rheumatoid factor (RF) or anti-citrullinated protein antibodies  
32 (ACPA)<sup>1</sup>. RA pathogenesis involves complex interactions between fibroblasts and cells of the  
33 innate and adaptive immune systems that lead to imbalanced secretion of pro- and anti-  
34 inflammatory cytokines<sup>2</sup>. Studies of RA pathology have reported markers for an activated  
35 synovial fibroblast state<sup>3,4</sup>, while others revealed the contribution of adaptive immune responses  
36 in isolated MHC class II-dependent T cells in response to the production of specific  
37 cytokines<sup>5,6,7</sup>. Activation and expansion of fibroblasts in the synovial lining also contributes to  
38 changes in the extracellular matrix, further contributing to bone and cartilage destruction<sup>8</sup>.  
39 Current existing therapies, mainly targeting the immune cell components, can reduce symptoms  
40 and progression, but only ~60% of patients respond adequately to these treatments<sup>9</sup>.

41  
42 Regions within sites of inflammation are filled with local accumulations of infiltrating  
43 leukocytes that form more or less organized structures. Such aggregates histologically resemble  
44 secondary lymphoid organs (SLOs) and are often termed tertiary lymphoid organs (TLOs)<sup>10</sup>.  
45 Patients with large and developed TLOs have been reported to respond more poorly to existing  
46 therapies<sup>11</sup>, but this is a topic of discussion in the field<sup>12,13</sup>. Recently, single cell RNA-Seq  
47 studies have uncovered additional fibroblast and immune cell types and states associated with  
48 RA and TLOs<sup>14,15</sup>. However, the spatial organization of these cells and their impact on TLO  
49 pathogenesis in RA remains unknown.

50

51 We have previously developed Spatial Transcriptomics<sup>16–18</sup> (ST), a method for high-throughput  
52 transcriptome profiling that retains spatial information in tissues<sup>16</sup>. In ST, transcriptomes are  
53 barcoded directly from frozen tissue sections. Tissue sections are placed on a glass slide covered  
54 with 1,000-2,000 features, each carrying a uniquely barcoded poly(d)T capture sequence  
55 enabling spatial mRNA capture. Tissue sections are then stained with Hematoxylin and Eosin  
56 (H&E) and imaged by transmitted light microscopy, followed by gentle permeabilization,  
57 mRNA capture on the poly(d)T probes and RNA-seq. Analysis of the resulting data provides a  
58 direct link between histology and RNA-seq.

59

60 Here, we used ST to spatially profile synovial tissues from seropositive and seronegative RA  
61 patients. To address the genomic variability and profile the TLO-like structures, we have studied  
62 gene expression as localized (2D) and three dimensional (3D) views. We report the resulting  
63 gene expression signatures, quantitative single-cell morphological features and patterns of cell  
64 migration patterns at the sites of synovial inflammation. This provides the first 3D, high-  
65 throughput transcriptomic view of rheumatoid arthritis-affected synovial biopsies.

66

## 67 **Results**

### 68 **3D spatial profiling of RA synovia**

69 To study the spatial organization in RA, we profiled 23 tissue sections by ST from five biopsies  
70 collected from RA patients at the time of joint replacement; specimens comprise three knee and  
71 two hip biopsies (**Fig. 1, Supplementary Table 1**). We optimized the technology for the tissue  
72 with the specific characteristics of synovia (**Methods, Supplementary Fig. 1**), collected profiles  
73 from consecutive sections, and aligned and interpolated the data to create a 3D view within each

74 biopsy (**Methods, Fig. 1**). This 3D sampling approach spanned larger distances creating the first  
75 exploratory multidimensional view of an RA synovial tissue biopsy.

76

## 77 **Variation within and between TLO-like structures in RA**

78 The biopsies from RA joints contained regions where infiltrating leukocytes (“infiltrates”)  
79 organize into cell-dense areas to form TLO-like aggregates<sup>19</sup> (**Fig. 2a, left**), which we annotated  
80 manually. We also detected TLOs automatically as regions of high density and distinct cellular  
81 topology (**Methods, Supplementary Fig. 2**). 80% of all manually-annotated infiltrates were in  
82 regions with a cell density score higher than 70% (**Supplementary Fig. 3**).

83

84 We then looked for differences between and within infiltrates in one biopsy (RA1, RF<sup>+</sup>ACPA<sup>+</sup>  
85 patient, knee, **Methods**). Analysis of spatially variable gene expression patterns revealed two  
86 clusters of infiltrate features in the TLO-like aggregates (**Methods, Supplementary Fig. 4**,  
87 **Supplementary Table 2**) varying in the expression of multiple genes including CD52, MS4A1  
88 and FN1 (**Supplementary Fig. 5**). These differences were found not only between aggregates  
89 but also within aggregates along its z-axis, which we could capture due to 3D sampling.

90

## 91 **Cytokine signaling from spatially resolved profiles of the RA synovium**

92 Next, using unsupervised clustering of the regions in the entire RA1 biopsy, we identified four  
93 major spatial domains: Cluster 1 included 87% of all annotated RA1 infiltrate data points (**Fig.**  
94 **2a, middle, Supplementary Table 3**), and Clusters 2-4 included the remainder and followed  
95 radial spatial patterns at consecutively increasing distance from the infiltrate Cluster 1 regions  
96 and had lower cell density scores (**Fig. 2a**).

97

98 In the RA1 Cluster 1 infiltrates, lymph node/TLO-associated genes (LTB and CCL19) and genes  
99 associated with B cells, T cells and their cross talk (CXCL13, CD52, MS4A1 and CD79A), were  
100 up-regulated (Wilcoxon's rank sum test,  $p \leq 0.05$ ), both as averaged signatures per spatial cluster  
101 (**Fig. 2b**) and as high-resolution spatial maps (**Fig. 2c**). CXCL13/CCL21 expression has  
102 previously been associated with formation of the spatial niches of T cells in model systems<sup>20</sup> and  
103 CXCL13 is also a key chemokine produced by T follicular and T peripheral helper (Tfh and Tph)  
104 cell subsets used in promoting B-cell mediated responses<sup>21</sup>. CXCL12/CCL19 expression, on the  
105 other hand, affects the spatial distributions of dendritic (DCs), B and plasma cells in TLOs<sup>20</sup>.  
106 Signaling driven by these cytokines has also been previously associated with overexpression of  
107 LTA and LTB<sup>20</sup>, a finding recapitulated in our spatially resolved data (Wilcoxon's rank sum test,  
108  $p \leq 0.05$ , **Fig. 2b-c**). In addition, we find downregulation of CXCL13 in TYROBP-high areas  
109 (present in 46% of all spatial Cluster 1 features) (**Fig. 2b-c, Supplementary Fig. 4b**). TYROBP-  
110 mediated ITAM pathway activity has previously been associated with immune cell co-  
111 modulation of bone cells in RA<sup>22</sup>.

112

113 In areas neighboring TLO-like aggregates (Clusters 2-4), gene expression was characterized by  
114 significantly increased (Wilcoxon's rank sum test,  $p \leq 0.05$ ) levels of metalloproteinases (MMP3,  
115 **Fig. 2c**) which are involved in extracellular matrix degradation. Fibronectin-1 expression (FN1,  
116 **Fig. 2c**), an extracellular matrix protein expressed by fibroblasts that induces transforming  
117 growth factor-beta secretion, and vascular cell adhesion molecule 1 expression (VCAM1, **Fig.**  
118 **2c**), were also upregulated, supporting the hypothesis that newly recruited hematopoietic cells  
119 are retained in the TLO-like structures<sup>23</sup>.

120

121 The spatial organization generalized by 3D ST profiling of consecutive sections in another joint-  
122 affected RA patient biopsy (RA2, RF<sup>+</sup>ACPA<sup>+</sup> patient, hip), with large infiltrates that spanned  
123 most of the sampled area (**Supplementary Fig. 6a**). Unsupervised clustering partitioned the  
124 regions to three major clusters having distinct spatial expression patterns (**Supplementary Table**  
125 **3**). Cluster 1 corresponded to the infiltrate areas (**Supplementary Fig. 6a**), comprising 90% of  
126 regions annotated by cellular morphology and high cell density (**Supplementary Fig. 7**), and the  
127 two other clusters formed a radial pattern. Key genes followed similar patterns to those in the  
128 RA1 sample, and included induction of CD52, LTB, CCL19 and MS4A1 infiltrates (Cluster 1,  
129 Wilcoxon's rank sum test,  $p \leq 0.05$ ) and increased FN1, MMP3 and PRG4 expression in the  
130 surrounding areas (Clusters 2-3, Wilcoxon's rank sum test,  $p \leq 0.05$ , **Supplementary Fig. 6b-d**).

131

132 **Dense volumetric analysis highlights chemokine driven T and B cell organization in TLO-**  
133 **like aggregates**

134 Closer examination of intra-infiltrate spatial patterns, distinguished T and B cell specific  
135 variation within the infiltrates (**Fig. 3, Supplementary Table 2**). For example, following  
136 infiltrate 6 (**Fig. 3, Supplementary Fig. 6a**) in 3D, we observed co-expression of CD52 and  
137 MS4A1 in highly localized patterns within TLO-like aggregates. Upregulation of CCL21/CCL19  
138 in RA2 (present in 75% of all Cluster 1 features), was accompanied with high expression of  
139 IL7R in 39% of spatial measurements (**Fig. 3**). In combination with CXCL13 upregulation in  
140 RA1, these data suggests a process of self-organization of T and B cells in TLO-like aggregates.  
141 We also reproduced our observation that CXCL13 is downregulated in TYROBP-high areas,  
142 which were present in 53% of all TLO-like spatial features. The CCL21<sup>+</sup> sites were restricted to

143 the centers, while MZB1<sup>+</sup>XBP1<sup>+</sup> sites were spatially overlaid with the outer rim of the TLO-like  
144 structures (**Fig. 3**), suggesting localized prevalence of plasma cells on the TLO-like edge sites.  
145 Similar analyses of the three additional samples (RA3-5) *i.e.* spatial and intra-infiltrate clustering  
146 was performed (**Supplementary Fig. 8a, Supplementary Tables 1-3**). RA3, a specimen from a  
147 patient having clinical characteristics similar to those of RA1-2 (RF<sup>+</sup>ACPA<sup>+</sup>), also exhibited  
148 significantly higher (Wilcoxon's rank sum test,  $p \leq 0.05$ ) expression of CD52 and MS4A1 in  
149 Cluster 1 that marked the cell dense infiltrate regions. These marker genes were also  
150 significantly higher (Wilcoxon's rank sum test,  $p \leq 0.05$ ) in the same cluster denoting the TLO-  
151 like structures in RA4-5 (RF<sup>-</sup>ACPA<sup>-</sup>, **Supplementary Fig. 8b**) although the overall expression  
152 of these markers was significantly lower (one-sided *t*-test,  $p \leq 0.05$ ) in the RF<sup>-</sup>ACPA<sup>-</sup>  
153 (seronegative) than in RF<sup>+</sup>ACPA<sup>+</sup> (seropositive) patients. In regions surrounding Cluster 1, RA3  
154 was again similar to the other two seropositive patients with upregulation of MMP3, FN1, PRG4  
155 and TYROBP in Clusters 2-3 (Wilcoxon's rank sum test,  $p \leq 0.05$ ). In seronegative patients, we  
156 did not detect the same gene expression patterns (**Supplementary Fig. 8b**). There, the same  
157 genes were instead found to be downregulated in the areas surrounding the TLO-structures  
158 (Wilcoxon's rank sum test,  $p \leq 0.05$ ). CCL19, which we and others reported as implicated in B  
159 cell distribution in the TLO sites, was also found to be significantly downregulated (Wilcoxon's  
160 rank sum test,  $p \leq 0.05$ ) in the TLO-structures of seronegative patients. This was also the opposite  
161 of what was observed in the three seropositive patients (**Supplementary Fig. 8b**).  
162

### 163 **Substantial variation in cell composition and spatial organization in the RA synovium**

164 To relate the spatial profiles to the cellular composition of RA regions, we used a previously  
165 published scRNA-seq reference<sup>14</sup> to define cell type specific signatures, and scored our spatial

166 regions in each of the five patients (**Fig. 4, Methods**). Out of the 13 cell types available in the  
167 reference<sup>14</sup>, plasma cells, macrophages, CD55<sup>+</sup> fibroblasts (F1) and THY1<sup>+</sup> fibroblasts (F2B)  
168 were found in every analyzed sample and section (**Supplementary Fig. 9**), while B cell  
169 abundances were significantly higher in the tissue volume of RA2 than in any other sample (one  
170 sided t-test,  $p<0.05$ ), with similar significantly spatially enriched (one sided t-test,  $p<0.05$ ) Tph  
171 cell type distributions in RA1 and DCs distributions in RA4.

172

173 In RA1-3, macrophage-enriched cell areas were on average significantly co-localized with higher  
174 presence of F2B fibroblast cells in the whole tissue volume (Pearson's R 0.93; 0.80; 0.72,  
175  $p<0.05$ , respectively RA1-3, **Supplementary Fig. 10a**). Additionally, in specific structures  
176 spanning both TLOs and surrounding areas in RA1-2, macrophage areas were found together  
177 with plasma cell areas (**Supplementary Fig. 10b-c**). In RA3, we observed a trend in which  
178 macrophage-rich areas were spatially correlated with F2B-rich areas in 2 out of the 9 TLO-like  
179 structures (Pearson's R 0.99,  $p<0.05$ , **Supplementary Fig. 10d**), whereas F2B-rich areas  
180 spatially surrounding the TLO-structures were exhausted of plasma cells (data not shown,  
181 Pearson's R -0.98,  $p<0.05$ ). Interestingly, while the TLO-like structures in RA1 and RA2 were  
182 dominated by both B cells and CD4<sup>+</sup> T cells, RA2 was again specific with significantly higher  
183 (one-sided *t*-test,  $p<0.05$ ) abundances of CD8<sup>+</sup> T cells and Tph cells. In RA3, CD8<sup>+</sup> T cells and  
184 Tph cells were not detected in the tissue and only few B cells were detected (**Supplementary**  
185 **Fig. 9**). No significant levels (one-sided *t*-test,  $p>0.05$ ) of either B or T cell scores were seen in  
186 RA4-5 in the tissue volume. Conversely, DCs were substantially increased in RA4-5 and not  
187 contained to specific areas in the tissue volume nor was their expression spatially correlated to B  
188 cell presence. This is the opposite of what was observed in RA1, in which tissues recruitment of

189 DCs in areas surrounding the infiltrates was associated with a decrease in B cells (Pearson's R -  
190 0.68,  $p < 0.05$ , **Supplementary Fig. 10e**). In RA2, which had the largest TLO-like structures and  
191 most B cells, DCs were few, their abundance significantly lower (one-sided t-test,  $p < 0.05$ ) as  
192 compared to all other tissue volumes but these DCs were also spatially contained to B cell sparse  
193 zones (Pearson's R -0.60,  $p < 0.05$ , **Supplementary Fig. 10e**).

194

195 **Connecting H&E and spatial transcriptomics reveals unified spatial clusters of**  
196 **morphological and molecular profiles features**

197 Connecting morphological data to tissue-specific molecular profiles<sup>24-27</sup> helps translating  
198 clinically relevant H&E information<sup>28,29</sup> to spatially resolved molecular signatures. We  
199 hypothesized that distinct cellular morphological features would also be reflected in different ST  
200 profiles and in other spatial features, such as cell density. To explore this, after cell segmentation  
201 of the H&E image accompanying spatial transcriptomics, we clustered the segmented cells by  
202 their morphological features (**Methods, Supplementary Fig. 11a**) and then examined their  
203 relation to other features from the H&E image and from ST.

204

205 Cluster1 (RA2), which represents the areas of infiltration, was enriched in specific H&E-derived  
206 cell clusters (**Supplementary Fig. 11b**), and those were, as expected, also regions of high  
207 cellular density of small cells across all samples (**Supplementary Fig. 11c,d**). Conversely,  
208 Cluster4 (in RA2) was prevalent in other H&E-defined cell clusters and those were associated  
209 with phenotypically large cell sizes (**Supplementary Fig. 11d**), in line with abundances of larger  
210 cell types like macrophages and fibroblasts in those distinct areas (**Supplementary Fig. 11e-f**).

211 Across all sections, we distinguished quantitative descriptions of cellular morphology and  
212 architecture in TLO-like areas and related them to single cell signatures (**viewable in** an  
213 extension we developed for histoCAT<sup>24</sup>, **Methods**).

214

## 215 **Discussion**

216 Spatially resolved genomic analysis of disease tissue holds promise for better precision  
217 phenotyping of patients and assessment of treatment responses in a manner that combines  
218 established histopathology with comprehensive molecular profiling. Here, we created an  
219 exploratory 3D spatial gene expression catalogue comprising high-resolution transcriptome-wide  
220 volumetric maps correlated to morphological features. This serves, to the best of our knowledge,  
221 as the first combined morphological, spatial and transcriptional blueprint of tissue from  
222 autoimmune disease patients, and spans multiple sections from five patient specimens.

223

224 The spatial clusters observed in synovial biopsies were distributed radially around the infiltrate  
225 sub-regions, further confirming the uniqueness of signals and cell types present in those areas,  
226 and highlighting the potential role of complex center-based TLO-like dynamics in these biopsies.

227 The spatial cell type organization throughout the 3D volume was transcriptionally connected to  
228 genes related to extracellular structure organization, regulation of B cell activation and  
229 proliferation, cytokine production and platelet degranulation in all analyzed samples.

230

231 Tph cells initiate B cell to plasma cell differentiation<sup>30,31</sup> and given CXCL13 and IL-21  
232 production, recruit more B cells to the TLO sites resulting in increased localized autoantibody  
233 and cytokine production<sup>32</sup>. Interestingly, 34% of these regions expressing Tph signature genes

234 included RASGRP2 overexpression in the RA2 seropositive patient tissue, a gene previously  
235 reported in the development of destructive arthritis<sup>33</sup>. Fibroblast cells surrounding TLOs have, on  
236 the other hand, been associated with propagation of T cell-rich zones and are considered marker  
237 features of lymphoid neogenesis<sup>34</sup>. The CD55<sup>+</sup> fibroblast population was present in the synovial  
238 lining (*i.e.* outer rim of the tissue) while CD90<sup>+</sup> (F2B) fibroblast populations were located closer  
239 to the TLO regions in all seropositive samples. Seronegative tissue volumes lacked robust signals  
240 of ongoing adaptive immune responses and were characterized by increased presence of DCs.  
241 DCs are involved in recruiting proinflammatory immune cells including macrophages,  
242 neutrophils and monocytes in RA<sup>35</sup>. Specifically in the seronegative tissue volumes, we report  
243 similar spatial cell distributions - the fibroblast populations as well as macrophages were  
244 significantly overexpressed (one-sided t-test, p<0.05) in the TLO structures; implicating a  
245 completely different immunological ‘drive’ in the sites of inflammation as compared to spatially  
246 deconvolved disease responses in seropositive tissues.

247  
248 Combining morphological features and high-throughput spatial signatures could aid in clinical  
249 diagnosis and overall disease management of RA. ST technology is compatible with  
250 conventional histological staining, has fast turnaround times and user-friendly laboratory setup.  
251 Future clinical studies using high-throughput spatially resolved transcriptomics<sup>36</sup> may be able to  
252 provide higher statistical power and more insights into monitoring disease severity and  
253 treatment-specific responses in seropositive and seronegative rheumatoid arthritis.

254

255 **Methods**

256 **Patient information and sample collection**

257 Synovial tissue biopsies from knee or hip joints were obtained during orthopedic replacement  
258 surgery. Additional patient information can be found in **Supplementary Table 1**. Ethical  
259 approvals were granted by the Ethics Committee of Karolinska University Hospital (2009/1262-  
260 31/3) and patients gave their informed written consent to participate in the study. The biopsies  
261 were snap frozen in isopentane prechilled with liquid nitrogen within 15 minutes of collection  
262 and kept at -80°C until embedding in OCT (Sakura, The Netherlands) and sectioning could be  
263 performed.

264

265 **Spatial transcriptomics**

266 Tissues were cryosectioned at 7 $\mu$ m thickness. Each section was carefully handled inside a  
267 cryotome (CryoStar NX70, Thermo Fisher Scientific, Life Technologies, Paisley, UK) and  
268 placed onto an individual array without any direct contact between the array surface and the  
269 cryotome as to avoid contamination. All sections were placed in the same fashion onto individual  
270 arrays. RA1 sections were sectioned at 21 $\mu$ m distance from each other while the RA2-5 sections  
271 were consecutives (z=7 $\mu$ m). The whole slide was then warmed for 1 min at 37°C and  
272 immediately fixed for 10 min at room temperature (RT) in a 2% formaldehyde solution (1:20  
273 37% formaldehyde acquired from Sigma-Aldrich, Missouri, USA in 1x PBS pH 7.4). The  
274 sections were dried with isopropanol and stained with hematoxylin and eosin (H&E). To ensure  
275 proper staining, the dried sections were incubated for 7 min with hematoxylin (Mayer's solution,  
276 Sigma-Aldrich, Missouri, USA) followed by 2 min in bluing buffer (DAKO, Agilent, California,  
277 USA) and 10 sec in eosin Y (1:20 in slightly acidic pH 6 Tris). To record both morphological  
278 and positional information, each tissue area was imaged at 20x resolution (Olympus, Japan)  
279 individually with a Metafer system (MetaSystems, Germany). Image stitching was performed

280 using VSide software provided by MetaSystems. The Spatial Transcriptomics protocol was  
281 carried out as previously described<sup>17,37,38</sup>. Sequencing was carried out on either the Nextseq 550  
282 (RA1-2) or Novaseq 6000 (RA3-5) instruments.

283

284 **Data mapping, annotation and filtering**

285 Data was pre-processed using a recently published pipeline<sup>39</sup>. Raw sequencing reads were  
286 demultiplexed using CASAVA according to the TruSeq LT index information. The forward read  
287 contained 28-30 nt; 18 nt spatial barcode followed by a semi-randomized 9 nt unique molecular  
288 identifier (UMI) (RA1-2) or randomized UMI (7 nts, RA3-5), while the reverse read contained  
289 the 50 nt transcript information. The first five bases in the reverse read were hard trimmed and  
290 then the rest of the read was quality trimmed based on the Burrows-Wheeler aligner. Trimmed  
291 reads were mapped to the human genome reference (GRCh38) using STAR<sup>40</sup>. Mapped reads  
292 were annotated based on Ensembl's v79 information and then paired with their forward read,  
293 UMI-filtered with a Hamming distance of 2 and counted using HTseq-count<sup>41</sup>. Quality control  
294 statistics were computed as number of paired reads per spatial barcode; number of UMI counts  
295 per spatial barcode and number of unique gene counts per spatial barcode. Data were normalized  
296 per biopsy using a linear regression approach<sup>42</sup> with a mean gene cutoff per ST spot prior to  
297 normalization as recommended by the developer.

298

299 **Image registration, alignment and visualization**

300 Images were randomly down-sampled to approximately the same image size per patient biopsy.  
301 In the RA1 biopsy, all sections were also cropped to contain approximately the same tissue areas.  
302 Image background was removed using scikit-image<sup>43</sup> before registering the sections using

303 SCALED\_ROTATION (biopsies RA1 and RA2) and RIGID\_BODY (biopsies RA3, RA4 and  
304 RA5) from PyStackReg<sup>44</sup>. Transformation matrices were used to align the spatially resolved  
305 count matrices in the same fashion. All of the following data processing was performed in R. As  
306 the spatially resolved data is of restricted resolution, the data was interpolated using the akima  
307 package in R over the tissue section area to aid in data interpretation. Volumetric expression  
308 heatmaps were created that could be viewed interactively using the developed RShiny  
309 application (<https://spatialtranscriptomics3d.shinyapps.io/3DSeTH/>).

310

311 **Single cell segmentation**

312 Single cell segmentation was performed by combining Ilastik 1.3.2<sup>45</sup> and CellProfiler 3.1.8<sup>46</sup>.  
313 Random forest classification implemented in Ilastik was used to train three distinct classes  
314 (nuclei, membrane, and background) to enable the prediction and export of probability maps.  
315 CellProfiler was then used to segment those exported probability maps to create labeled single  
316 cell masks for downstream analysis.

317

318 **Coupling single cell topology to ST data**

319 ST 100µm barcoded area locations were used to crop areas of 200x200 pixels from the  
320 corresponding H&E images. These cropped and segmented images and imported into  
321 histoCAT<sup>24</sup> for single cell quantification and spatial analysis. ST based phenotypic clusters were  
322 matched to the single cell data as well as the manual infiltrate annotations. Each image was  
323 saved as an individual interactive session for histoCAT loading.

324

325 **Phenotyping cell type calling**

326 We used PhenoGraph<sup>47</sup> with the code in <https://github.com/jacoblevine/PhenoGraph> to define  
327 phenotypic groups (PG) based on the morphological single cell readouts. We used histoCAT<sup>24</sup> to  
328 extract mean marker expression as well as morphological features from the single cell mask. The  
329 default setting (30 nearest neighbors) was used to define 25 distinct phenotypic groups using a  
330 fixed seed for the Louvain method (random seed: 2).

331

### 332 **Spatially resolved DE analysis**

333 To cluster regions, most variable genes were selected as previously described<sup>42</sup> and principal  
334 component analysis (PCA) performed on the subsampled and normalized *region x gene*  
335 expression matrices, followed by two dimensional *t*-stochastic neighbor embedding (tSNE)<sup>48</sup>.  
336 Hierarchical clustering was done on the 3D tSNE reduced data to determine numbers of  
337 individual clusters present in the whole tissue volume followed by differential expression (DE)  
338 analysis using a likelihood ratio test<sup>49</sup>. DE genes between the clusters were called as  
339 differentially expressed<sup>18</sup> if satisfying the following criteria:  $p < 0.001$  and  $\log \text{ratio} > 0.5$ .

340

### 341 **Single cell signatures**

342 Single cell type signatures were downloaded from Stephenson *et al*<sup>14</sup>, and the top 200 markers  
343  $m_l$  were kept for each cell type  $l$  with the following criteria: average log fold change $>1$  and  
344  $\text{FDR} < 5\%$ . A total of 13 cell types were present in the reference. ST matrix is defined as  
345 *region x gene* matrix for a total of  $i$  regions and  $j$  genes. To score each cell type  $c_{l,r}$  assignment  
346 per each individual spatial feature  $S_{i,j}$ , the normalized ST matrix for was first subset for  $m_l$  if  
347 more than 3  $m_l$  genes for each  $S_{i,j}$  were present; creating a  $R \times K$  matrix. Then, we computed the

348 correlation coefficient over each  $S_{i,j}$  for each pair of genes  $(j, k)$  and a total of  $R$  regions such

349 that:

350 
$$\underline{X_j} = \frac{1}{R} \sum_{r=1}^R X_{j,r}, j = [1, K]$$

$$Cov_{j,k} = \frac{1}{R} \sum_{r=1}^R (X_{j,r} - \underline{X_j})(X_{k,r} - \underline{X_k}), k = [1, K]$$

351 
$$Corr_{j,k} = \frac{Cov_{j,k}}{\sqrt{Cov_{j,j}Cov_{k,k}}},$$

352 A gene-to-gene co-expression score was considered valid if  $Corr_{j,k} > 0.2$  and these genes  $M$

353 were used in all further analysis. Now, the spatial matrix was subset to create a  $R \times M$  matrix

354 used in the cell typing task and a cell type expression score  $c_{l,r}$  for each gene expression value

355  $Y_{m,r}$  was calculated:

$$c_{l,r} = \sum_{m=1}^M Y_{m,r}$$

356 The cell type assignment  $c_{l,r}$  was then scaled between the different cell types present in all the

357 regions:

$$c_{max} = \max_r c_{l,r},$$

$$C_{l,r} = \frac{c_{l,r}}{c_{max}}$$

358 To represent proportions of cell types in each region, we finally scaled the data by the

359 cumulative cell type score calculated for the region such that:

$$c_{sum} = \sum_{r=1}^R C_{l,r}, l = [1, 13]$$

$$C_{l,r} = \frac{C_{l,r}}{c_{sum}}$$

360  $C_{l,r}$  represented the approximated contribution of each cell type  $l$  in each region  $r$ . The gene  
361 signatures  $M$  were also tested for functional enrichment with Gene Ontology terms with  
362 PANTHER<sup>50</sup>. We reported all terms at 5% FDR.

363

364 **Data and materials availability:** Raw sequencing data is available through an MTA with  
365 Vivianne Malmström ([vivianne.malmstrom@ki.se](mailto:vivianne.malmstrom@ki.se)). All processed data files are available at the  
366 Single Cell Portal ([https://portals.broadinstitute.org/single\\_cell/study/SCP460/](https://portals.broadinstitute.org/single_cell/study/SCP460/)).

367

368 **Code availability:** All code has been deposited to <https://github.com/klarman-cell-observatory/3dst>.

370

371 **References**

- 372 1. Malmström, V., Catrina, A. I. & Klareskog, L. The immunopathogenesis of seropositive  
373 rheumatoid arthritis: from triggering to targeting. *Nat. Rev. Immunol.* **17**, 60–75 (2017).
- 374 2. McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. *Nat. Rev. Immunol.* **7**, 429–442 (2007).
- 376 3. Pap, T. *et al.* Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of  
377 the tumour suppressor PTEN at sites of invasive growth and destruction. *Arthritis Res.* **2**,  
378 59–64 (2000).
- 379 4. Gravallese, E. M., Darling, J. M., Ladd, A. L., Katz, J. N. & Glimcher, L. H. In situ  
380 hybridization studies of stromelysin and collagenase messenger RNA expression in  
381 rheumatoid synovium. *Arthritis Rheum.* **34**, 1076–1084 (1991).
- 382 5. Okada, Y. *et al.* Genetics of rheumatoid arthritis contributes to biology and drug discovery.

383        *Nature* **506**, 376–381 (2014).

384        6. Pradeu, T., Jaeger, S. & Vivier, E. The speed of change: towards a discontinuity theory of  
385        immunity? *Nat. Rev. Immunol.* **13**, 764–769 (2013).

386        7. Ye, C. J. *et al.* Intersection of population variation and autoimmunity genetics in human T  
387        cell activation. *Science* vol. 345 1254665–1254665 (2014).

388        8. Bartok, B. & Firestein, G. S. Fibroblast-like synoviocytes: key effector cells in rheumatoid  
389        arthritis. *Immunol. Rev.* **233**, 233–255 (2010).

390        9. Kerschbaumer, A. *et al.* Efficacy of pharmacological treatment in rheumatoid arthritis: a  
391        systematic literature research informing the 2019 update of the EULAR recommendations  
392        for management of rheumatoid arthritis. *Ann. Rheum. Dis.* **79**, 744 (2020).

393        10. Aloisi, F. & Pujol-Borrell, R. Lymphoid neogenesis in chronic inflammatory diseases.  
394        *Nature Reviews Immunology* vol. 6 205–217 (2006).

395        11. Cañete, J. D. *et al.* Clinical significance of synovial lymphoid neogenesis and its reversal  
396        after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. *Ann. Rheum. Dis.* **68**,  
397        751–756 (2009).

398        12. Klaasen, R. *et al.* The relationship between synovial lymphocyte aggregates and the clinical  
399        response to infliximab in rheumatoid arthritis: a prospective study. *Arthritis Rheum.* **60**,  
400        3217–3224 (2009).

401        13. Lewis, M. J. *et al.* Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and  
402        Treatment Response Phenotypes. *Cell Rep.* **28**, 2455–2470.e5 (2019).

403        14. Stephenson, W. *et al.* Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-  
404        cost microfluidic instrumentation. *Nat. Commun.* **9**, 791 (2018).

405        15. Zhang, F. *et al.* Defining inflammatory cell states in rheumatoid arthritis joint synovial

406 tissues by integrating single-cell transcriptomics and mass cytometry. *Nat. Immunol.* (2019)

407 doi:10.1038/s41590-019-0378-1.

408 16. Ståhl, P. L. *et al.* Visualization and analysis of gene expression in tissue sections by spatial

409 transcriptomics. *Science* **353**, 78–82 (2016).

410 17. Carlberg, K. *et al.* Exploring inflammatory signatures in arthritic joint biopsies with Spatial

411 Transcriptomics. *Sci. Rep.* **9**, 18975 (2019).

412 18. Vickovic, S. *et al.* Massive and parallel expression profiling using microarrayed single-cell

413 sequencing. *Nat. Commun.* **7**, 13182 (2016).

414 19. Timmer, T. C. G. *et al.* Inflammation and ectopic lymphoid structures in rheumatoid arthritis

415 synovial tissues dissected by genomics technology: identification of the interleukin-7

416 signaling pathway in tissues with lymphoid neogenesis. *Arthritis Rheum.* **56**, 2492–2502

417 (2007).

418 20. Luther, S. A. *et al.* Differing activities of homeostatic chemokines CCL19, CCL21, and

419 CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. *J.*

420 *Immunol.* **169**, 424–433 (2002).

421 21. Rao, D. A. *et al.* Pathologically expanded peripheral T helper cell subset drives B cells in

422 rheumatoid arthritis. *Nature* **542**, 110–114 (2017).

423 22. Crotti, T. N. *et al.* The immunoreceptor tyrosine-based activation motif (ITAM) -related

424 factors are increased in synovial tissue and vasculature of rheumatoid arthritic joints.

425 *Arthritis Res. Ther.* **14**, R245 (2012).

426 23. Jones, G. W., Hill, D. G. & Jones, S. A. Understanding Immune Cells in Tertiary Lymphoid

427 Organ Development: It Is All Starting to Come Together. *Front. Immunol.* **7**, 401 (2016).

428 24. Schapiro, D. *et al.* histoCAT: analysis of cell phenotypes and interactions in multiplex

429 image cytometry data. *Nat. Methods* **14**, 873–876 (2017).

430 25. Damond, N. *et al.* A Map of Human Type 1 Diabetes Progression by Imaging Mass  
431 Cytometry. *Cell Metab.* **29**, 755–768.e5 (2019).

432 26. Schulz, D. *et al.* Simultaneous Multiplexed Imaging of mRNA and Proteins with Subcellular  
433 Resolution in Breast Cancer Tissue Samples by Mass Cytometry. *Cell Syst* **6**, 531 (2018).

434 27. Xu, R. *et al.* Spatial-Resolution Cell Type Proteome Profiling of Cancer Tissue by Fully  
435 Integrated Proteomics Technology. *Anal. Chem.* **90**, 5879–5886 (2018).

436 28. Orange, D. E. *et al.* Histologic and transcriptional evidence of subclinical synovial  
437 inflammation in rheumatoid arthritis patients in clinical remission. *Arthritis Rheumatol*  
438 (2019) doi:10.1002/art.40878.

439 29. Bankhead, P. *et al.* QuPath: Open source software for digital pathology image analysis. *Sci.*  
440 *Rep.* **7**, 16878 (2017).

441 30. Rao, D. A. *et al.* Pathologically expanded peripheral T helper cell subset drives B cells in  
442 rheumatoid arthritis. *Nature* **542**, 110–114 (2017).

443 31. Cannons, J. L. *et al.* Optimal germinal center responses require a multistage T cell:B cell  
444 adhesion process involving integrins, SLAM-associated protein, and CD84. *Immunity* **32**,  
445 253–265 (2010).

446 32. Shen, P. & Fillatreau, S. Antibody-independent functions of B cells: a focus on cytokines.  
447 *Nat. Rev. Immunol.* **15**, 441–451 (2015).

448 33. Nakamura, H. *et al.* Ectopic RASGRP2 (CalDAG-GEFI) expression in rheumatoid  
449 synovium contributes to the development of destructive arthritis. *Ann. Rheum. Dis.* **77**,  
450 1765–1772 (2018).

451 34. Pitzalis, C., Jones, G. W., Bombardieri, M. & Jones, S. A. Ectopic lymphoid-like structures

452 in infection, cancer and autoimmunity. *Nat. Rev. Immunol.* **14**, 447–462 (2014).

453 35. Yu, M. B. & Langridge, W. H. R. The function of myeloid dendritic cells in rheumatoid

454 arthritis. *Rheumatology International* vol. 37 1043–1051 (2017).

455 36. Maniatis, S. *et al.* Spatiotemporal dynamics of molecular pathology in amyotrophic lateral

456 sclerosis. *Science* **364**, 89–93 (2019).

457 37. Berglund, E. *et al.* Automation of Spatial Transcriptomics library preparation to enable rapid

458 and robust insights into spatial organization of tissues. *BMC Genomics* **21**, 1–10 (2020).

459 38. Salmén, F. *et al.* Barcoded solid-phase RNA capture for Spatial Transcriptomics profiling in

460 mammalian tissue sections. *Nat. Protoc.* **13**, 2501–2534 (2018).

461 39. Navarro, J. F., Sjöstrand, J., Salmén, F., Lundeberg, J. & Ståhl, P. L. ST Pipeline: an

462 automated pipeline for spatial mapping of unique transcripts. *Bioinformatics* **33**, 2591–2593

463 (2017).

464 40. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21

465 (2013).

466 41. Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with high-

467 throughput sequencing data. *Bioinformatics* **31**, 166–169 (2015).

468 42. Lun, A. T. L., Bach, K. & Marioni, J. C. Pooling across cells to normalize single-cell RNA

469 sequencing data with many zero counts. *Genome Biol.* **17**, 75 (2016).

470 43. van der Walt, S. *et al.* scikit-image: image processing in Python. *PeerJ* **2**, e453 (2014).

471 44. Thévenaz, P., Ruttimann, U. E. & Unser, M. A pyramid approach to subpixel registration

472 based on intensity. *IEEE Trans. Image Process.* **7**, 27–41 (1998).

473 45. Sommer, C., Straehle, C., Kothe, U. & Hamprecht, F. A. Ilastik: Interactive learning and

474 segmentation toolkit. *2011 IEEE International Symposium on Biomedical Imaging: From*

475        *Nano to Macro* (2011) doi:10.1109/isbi.2011.5872394.

476        46. Lamprecht, M. R., Sabatini, D. M. & Carpenter, A. E. CellProfiler: free, versatile software  
477        for automated biological image analysis. *Biotechniques* **42**, 71–75 (2007).

478        47. Levine, J. H. *et al.* Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like  
479        Cells that Correlate with Prognosis. *Cell* **162**, 184–197 (2015).

480        48. Chung, N. C. & Storey, J. D. Statistical significance of variables driving systematic  
481        variation in high-dimensional data. *Bioinformatics* **31**, 545–554 (2015).

482        49. McDavid, A. *et al.* Data exploration, quality control and testing in single-cell qPCR-based  
483        gene expression experiments. *Bioinformatics* **29**, 461–467 (2013).

484        50. Mi, H. *et al.* PANTHER version 11: expanded annotation data from Gene Ontology and  
485        Reactome pathways, and data analysis tool enhancements. *Nucleic Acids Res.* **45**, D183–  
486        D189 (2017).

487        **Acknowledgments**

488        We thank Jennifer Rood for help with manuscript preparation and Ania Hupalowska for  
489        illustrations. This research was funded by the Knut and Alice Wallenberg Foundation (S.V.,  
490        A.C.), the Royal Swedish Academy of Sciences and Swedish Society for Medical Research  
491        (S.V.); FOREUM, Foundation for Research in Rheumatology, European Research Council  
492        (CoG 2017 - 7722209) and the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse  
493        (A.C.); the Margareta af Ugglas stiftelse (V.M.), the Swedish Rheumatism Association (M.K.,  
494        V.M.), the Swedish Research Council (V.M., P.L.S), Science for Life Laboratory (P.L.S.) and  
495        the Klarman Cell Observatory and HHMI (A.R.). D.S. was supported by the University of Zurich  
496        BioEntrepreneur-Fellowship (BIOEF-17-001) and a Swiss National Science Foundation Early  
497        Postdoc Mobility fellowship (P2ZHP3\_181475); D.S and P.K.S were supported by NCI grant

498 U54-CA225088. S.V. was supported as a Knut and Alice Wallenberg Fellow at the Broad  
499 Institute of MIT and Harvard.

500

501 **Contributions**

502 S.V. and V.M. designed the study; K.C. performed experiments with supervision from P.L.S.;  
503 S.V. designed the analysis and analyzed the data with help from L.L. and B.L.; S.V.  
504 implemented the Shiny extension; D.S. designed the histoCAT extension and phenotypic  
505 analysis workflows with supervision from P.K.S. and A.R.; M.K. annotated all images; A.I.C.  
506 and A.H.H. provided samples for the study; S.V. and A.R. wrote the manuscript with input from  
507 all the authors. All the authors read the manuscript and discussed the results.

508

509 **Competing interests**

510 S.V and P.L.S. are authors on patents applied for by Spatial Transcriptomics AB (10X Genomics  
511 Inc) covering the technology. P.L.S. and K.C. are scientific consultants to 10x Genomics Inc.  
512 P.K.S is on the SAB or BOD of Rarecyte Inc, Applied Biomath LLC, Glencoe Software Inc. and  
513 Nanostring Inc.; none of these relationships are directly related to the topic of this study. A.R. is  
514 a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics  
515 and until August 31, 2020 was an SAB member of Syros Pharmaceuticals, Neogene  
516 Therapeutics, Asimov and ThermoFisher Scientific. From August 1, 2020, A.R. is an employee  
517 of Genentech, a member of the Roche Group. S.V. and A.R. are co-inventors on  
518 PCT/US2020/015481 relating to this work.

519

520 **Tables**

521 **Supplementary Table 1.** Patient information.

522 **Supplementary Table 2.** Differentially expressed genes in infiltrate structures (RA1-5).

523 **Supplementary Table 3.** Differentially expressed genes in all tissue sections (RA1-5).

524

525 **Figures**

526 **Fig. 1. Sampling and spatial barcoding of rheumatoid arthritis samples.** Synovial tissue  
527 from two sites, hip and knee, was sampled and the biopsies cryopreserved in OCT compound.

528 The biopsies were cryosectioned and placed on a spatially barcoded microarray. Tissue sections  
529 were H&E stained and the images recorded. While recording histology, positional information of  
530 each spatial (x,y) feature was also tracked. Cells in the tissue were gently permeabilized and  
531 mRNA molecules captured on the spatially barcoded poly(d)T capture probes. The cDNA  
532 synthesis reaction was performed on the slide surface and mRNA information copied. Libraries  
533 were prepared and pair-end sequenced. The data was processed so that spatially barcoded  
534 expression information and the morphological images were registered and aligned. This resulted  
535 in spatial data transformation, interpolation and imminent visualization.

536

537 **Fig. 2. Spatial data clustering in RA1.** (a) Morphological annotation, spatial clustering (color  
538 code) and CD52 spatial expression (color scale). Pink marks spatial infiltrate positions that  
539 overlap between the morphological annotation and spatial clustering (Cluster1). (b) Average  
540 expression of genes found in different spatial clusters. Statistical significance markings  
541 (Wilcoxon's rank sum test) are displayed;  $0.005 < p \leq 0.05$  (\*). (c) Spatial expression of nine  
542 differentially expressed genes as determined by clustering. Color-scale denotes gene expression  
543 and is shared between panels (a) and (c). Color code is shared between panels (a) and (b).

544 **Fig. 3. RA2 infiltrate dynamics.** Zoomed in expression (color scale) of spatial clusters followed  
545 by seven example genes (rows) in the Infiltrate6 region across in RA2 sections (columns).

546  
547 **Fig. 4. Spatial distribution of cell types in the rheumatoid arthritis synovium.** Most  
548 abundant cell types (color scale) shown in each of the five RA patient samples (columns) and  
549 across all spatially prof **Supplementary information for:**

550  
551 **Supplementary Figures**

552 **Supplementary Figure 1. Fluorescent footprint and sequencing library statistics.** **(a)** Images  
553 of H&E stained tissue sections and corresponding fluorescent cDNA expression footprints  
554 marking spatial gene activity for RA1 (knee) and RA2 (hip) patient biopsies. cDNA signal shows  
555 optimized tissue handling for both RA sampling sites. **(b)** Sequencing library statistics for all  
556 patient biopsies (RA1-5) reporting number of raw sequencing reads, UMIs and unique protein  
557 coding gene counts per 100 $\mu$ m spatial feature.

558  
559 **Supplementary Figure 2. Single cell segmentation and histoCAT analysis workflow.** **(a)**  
560 100 $\mu$ m ST features were used to crop the respective H&E images as 100 $\mu$ m x 100 $\mu$ m areas.  
561 Ilastik software was used to train a random-forest classifier to create probabilities for three  
562 classes in the H&E image (red: nuclei; green: membrane; blue: background). Those probabilities  
563 were segmented using the CellProfiler software. Single cell areas (each cell has a discrete color  
564 code) and density (color scale represents the percent of each cell's area touching a membrane of  
565 a neighboring cell) were quantified and visualized in the histoCAT software. In these

566 representations, black background color denotes no cells were detected. **(b)** Same as in (a) for a  
567 less cell dense area overlapping a 100 $\mu$ m ST feature.

568

569 **Supplementary Figure 3. Cellular morphology reproduces manual annotations.** On average  
570 80.20% of manually annotated infiltrates (red octagons) were present in ST features with a  
571 density higher than 70 in all sections (left boxplot in pair) while at the same density threshold,  
572 91% of all Cluster1 ST features were present in cell dense areas (red circle; right boxplot in pair).

573

574 **Supplementary Figure 4. Clustering analysis of RA1 infiltrate regions.** **(a)** PCA plot of each  
575 individual spatially resolved infiltrate feature present in any of the RA1 tissue sections. Samples  
576 have been color-coded based on hierarchical clusters (cyan; purple). **(b)** Heatmap of  
577 differentially expressed genes (color scale, rows) between the two clusters (color code, columns)  
578 as determined in (a). Color code is shared between the panels.

579

580 **Supplementary Figure 5. Spatial averages of annotated infiltrates in four RA1 biopsy**  
581 **sections.** **(a)** Volumetric morphological view with overlaid color-coded infiltrate regions present  
582 in all four sections as determined by clustering (color code). Yellow arrow marks an event where  
583 the infiltrate region changed its cluster assignment. **(b)** Barplots showing average expression of  
584 three cluster driving genes; CD52; MS4A1 and FN1. Infiltrate regions are number coded (1-5)  
585 and the numbering is shared between the panels. Error bars represent s.e.m. where more than one  
586 spatial data point was present.

587

588 **Supplementary Figure 6. Spatial gene expression in the RA2 patient biopsy. (a)** Spatial  
589 clustering (color code) as compared to morphological annotation and infiltrate clustering (color  
590 code). Pink (color code) marks infiltrate regions that we found as overlapping between the  
591 morphological annotation and spatial clusters (Cluster1). Color codes are shared between the  
592 panels. **(b)** Average expression of some spatially variable genes in the clusters. Wilcoxon's rank  
593 sum test for PRG4, MMP3, FN1 and TYROBP denotes difference in Cluster 1 lesser than in  
594 another cluster while for the rest of the genes, the same denotation describes differences greater  
595 in Cluster 1 than the rest. Statistical significance markings (Wilcoxon's rank sum test) are  
596 displayed;  $p>0.5$  (ns),  $0.005 < p \leq 0.05$  (\*),  $0.0005 < p \leq 0.005$  (\*\*),  $p \leq 0.0005$  (\*\*\*) . **(c)** Heatmap of  
597 gene expression (color scale) where each column represents one spatial feature and each row a  
598 gene. Spatial features (columns) have been color-coded in the top panel into two annotation  
599 categories (pink; annotated infiltrates and dark grey; rest other annotation). In the bottom  
600 annotation panel, spatial features were color coded based on their spatial cluster identities as  
601 determined in (a). Example genes (rows) have been highlighted in the image. **(d)** Heatmap of  
602 differentially expressed genes (color scale, rows) between the three infiltrate clusters (color code,  
603 columns) as determined by infiltrate clustering in (a). Example genes (rows) have been  
604 highlighted in the image.

605  
606 **Supplementary Figure 7. Cellular morphology improves manual annotation in RA2 patient**  
607 **sections.** On average 90% of manually annotated infiltrates (red octagons) were present in ST  
608 features with a density higher than 70% in all sections (left boxplot in pair) while at the same  
609 density threshold, 84% of all Cluster1 ST features were present in cell dense areas (red circle;  
610 right boxplot in pair).

611

612 **Supplementary Figure 8. Spatial and infiltrate clustering for RA3-5 patient biopsies. (a)**

613 Spatial clustering (color code) as compared to clustering of only infiltrate regions (color code).

614 Pink (color code) marks infiltrate regions that we found as overlapping between the

615 morphological annotation and spatial clusters (Cluster1). **(b)** Average expression of some

616 spatially variable genes in the clusters. For RA3, Wilcoxon's rank sum test for PRG4, MMP3,

617 FN1 and TYROBP denotes difference in Cluster 1 lesser than in another cluster while for the rest

618 of the genes, the same denotation describes differences greater in Cluster 1 than the rest. For

619 RA4, all differences are described as greater while for RA5; PRG4, FN1 and TYROBP are only

620 genes that denote lesser significant expression in Cluster 1. Statistical significance markings

621 (Wilcoxon's rank sum test) are displayed;  $p>0.5$  (ns),  $0.005 < p \leq 0.05$  (\*),  $0.0005 < p \leq 0.005$  (\*\*),

622  $p \leq 0.0005$  (\*\*\*)

623

624 **Supplementary Figure 9. Single cell distributions in the tissue volume.** Cell type percentage

625 of 13 tested cell types (color code) shown in each section (column) and divided in groups of

626 TLO infiltrates or the rest of the tissue ("Rest").

627

628 **Supplementary Figure 10. Correlations between different spatial cell type abundances in**

629 **the rheumatoid arthritis synovium. (a)** Correlation plots between macrophage and F2B

630 abundances in the whole tissue volume in RA1-3. **(b-c)** Correlation plots between macrophage

631 and plasma cell abundances in infiltrates or surrounding regions ("rest") in RA1 and RA2. **(d)**

632 Correlation plots between macrophage and F2B abundances in two infiltrate regions in RA3. **(e)**

633 Correlation plots between dendritic cell (DCs) and F2B abundances in the whole tissue volume

634 in RA1 and RA2. Reported are Pearson's correlation coefficients (R) and empirical p values for  
635 each comparison.

636

637 **Supplementary Figure 11. Dimensionality reduced RA2 topological features correlate with**  
638 **cell type expression.** **(a)** 25 phenotypic groups (PG) clustering visualized in tSNE projection.  
639 **(b)** ST cluster color codes overlaid on top of (a). **(c)** Cell density as percent cells touching  
640 another cell overlaid on top of (a). **(d)** Cell area overlaid on top of (a). **(e)** Macrophage cell type  
641 score overlaid on top of (a). **(f)** Fibroblast (F2B) cell type score overlaid on top of (a).

# Fig1




Fig2




**a****b****c**

Fig3

bioRxiv preprint doi: <https://doi.org/10.1101/2020.12.10.420463>; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.






Fig4




## SuppFig1


a




b





SuppFig2





### SuppFig3











## SuppFig6








## SuppFig9





# SuppFig11

bioRxiv preprint doi: <https://doi.org/10.1101/2020.12.10.420463>; this version posted December 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

